Although 11C-choline was FDA approved for recurrent prostate cancer PET scans in 2013, it is no longer widely used compared to targeted radiotracers for prostate cancer due to its inferior detection rates when PSA is low [36]. This evidence concerns the gene KLK3 and prostate cancer.